Watch the webcasts from our industry partners Satellite Symposia
Immuno-Oncology Treatment Paradigms for First-Line ES-SCLC and Unresectable Stage III NSCLC: a Case-Based Programme
AstraZeneca
-
Welcome and introduction
L. Paz-Ares (Madrid, Spain) -
The role of immuno-oncology combinations in ES-SCLC: A clinical case study
A. Ardizzoni (Bologna, Italy) -
Treating unresectable Stage III NSCLC with immuno-oncology: A clinical case study
F. Barlesi (Villejuif, France) - Live panel discussion and audience Q&A
A. Speakers (, Switzerland) - Meeting close
L. Paz-Ares (Madrid, Spain)
2020 in Review: Recent Advances in Immuno-Oncology Combinations and Cellular Therapies
Bristol Myers Squibb
-
Welcome and Introduction
George Coukos (Lausanne, Switzerland) -
Hallmarks of IO combination
James Larkin (London, United Kingdom) -
Expanding the Immune System by Cellular Therapies
Michael Hudecek (Würzburg, Germany) -
Podium Discussion
All Speakers
Perspectives on The Role of Circulating Tumour DNA
Hoffmann-La Roche Ltd.
-
Welcome and introduction: circulating tumour DNA and its role in the management of patients with cancer
J. Bellmunt (Boston, United States of America) -
Current status on circulating tumour DNA and its future role in clinical practice
J. Gschwend (Munich, Germany) -
Circulating tumour DNA as an emerging biomarker in urothelial cancer
J. Bellmunt (Boston, United States of America) - Live Q&A and discussion